Page 1

燃 石 医学 Burning Rock Dx Burning Rock Reports First Quarter 2021 Financial Results May 25 , 2021 GUANGZHOU , China , May 25 , 2021 ( GLOBE NEWSWIRE ) -- Burning Rock Biotech Limited ( NASDAQ : BNR , the " Company " or " Burning Rock " ) , a company focused on the application of next generation sequencing ( NGS ) technology in the field of precision oncology , today reported financial results for the three months ended March 31 , 2021 . Recent Business Highlights • Early Detection • Launched the 11,873 - subject PRESCIENT ( Pan - canceR Early - Stage detection by Ilquid Biopsy technique project ) study for developing our 22 - cancer early detection test . This is in addition to our ongoing PREDICT ( Pan - CanceR Early Detection ProjeCT ) study for the development of our 9 - cancer early detection test . • Presented at the 10th National Health Check - up Department Directors Summit ( April 23 - April 25 , 2021 ) , where our early detection technology platform , product performance data and clinical programs were discussed at a keynote presentation . • Therapy Selection o Achieved strong performance in the FDA - led SEQC2 ( sequencing quality control ) study . Full results of the liquid biopsy study were published in Nature Biotechnology ( article link here ) , and results of the targeted tissue - based panels were also published separately ( article link here ) . • Featured in the 2021 " Consensus on Colorectal Cancer High - throughput Sequencing Molecular Diagnostics in China , " 1 in which our NGS - based bioinformatics algorithm for microsatellite instability ( MSI ) detection was endorsed and recommended . • Pharma Services • Launched with Abbisko Therapeutics the companion diagnostics ( CDx ) development for ABSK091 , which is an innovative small molecule FGFR inhibitor that has obtained National Medical Products Administration ( NMPA ) investigational new drug ( IND ) approval for the treatment of patients with urothelial carcinoma . First Quarter 2021 Financial Results Revenues were RMB106.6 million ( US $ 16.3 million ) for the three months ended March 31 , 2021 , representing a 58.4 % increase from RMB67.3 million for the same period in 2020 , or a 19.1 % sequential decrease from RMB131.7 million for the three months ended December 31 , 2020. The sequential decrease was primarily due to negative impact associated with the COVID - 19 pandemic in January 2021 and seasonality during the Chinese New Year holidays in February 2021 . • Revenue generated from central laboratory business was RMB74.6 million ( US $ 11.4 million ) for the three months ended March 31 , 2021 , representing a 61.6 % increase from RMB46.1 million for the same period in 2020 , primarily attributable to the year - on - year volume growth of the central laboratory business . Number of patients tested in the central laboratory channel was 7,716 for the three months ended March 31 , 2021 , representing a 64.9 % increase from 4,680 for the same period in 2020 . • Revenue generated from in - hospital business was RMB29.0 million ( US $ 4.4 million ) for the three months ended March 31 , 2021 , representing a 69.3 % increase from RMB17.1 million for the same period in 2020. Number of contracted partner hospitals in the in - hospital channel increased to 32 as of March 31 , 2021 from 29 as of December 31 , 2020 and 21 as of March 31 , 2020 . • Revenue generated from pharma research and development services was RMB3.1 million ( US $ 0.5 million ) for the three months ended March 31 , 2021 , representing a 24.5 % decrease from RMB4.1 million for the same period in 2020 , due to less pharmaceutical testing performed during the quarter , while the pipeline of our pharmaceutical projects has been building over time .